Novacea Licences Cancer Therapy to Schering-Plough for US$452 M
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 85 (Table of Contents)
Published: 7 Jul-2007
DOI: 10.3833/pdr.v2007.i85.320 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novacea and Schering-Plough entered into worldwide license agreement for Novacea’s Asentar™ (DN-101), which is phase 3 clinical trials for treating prostate cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS